Exclusive Summary

• High technical barriers in microsphere formulation severely limit global generic competition despite expired patents, offering a highly profitable blue-ocean opportunity.
• Targets over 64 million global distinct patients with schizophrenia and bipolar disorder, meeting the rigid clinical demand to combat fatal non-adherence and relapse.
• API strictly complies with USP and EP standards, backed by a successful product launch in China, ensuring robust regulatory readiness for cross-border registration.
• Scaled mass production of this complex injectable empowers distinct cost advantages over the originator, granting overseas distributors immense pricing flexibility and tender strength.